中华放射肿瘤学杂志
中華放射腫瘤學雜誌
중화방사종류학잡지
CHINESE JOURNAL OF RADIATION ONCOLOGY
2015年
3期
237-240
,共4页
王鹏%刘维帅%徐利明%王帅%庞青松%袁智勇%王军%赵路军%王平
王鵬%劉維帥%徐利明%王帥%龐青鬆%袁智勇%王軍%趙路軍%王平
왕붕%류유수%서리명%왕수%방청송%원지용%왕군%조로군%왕평
癌,小细胞肺/放化疗法%老年%放化疗法,同期%放化疗法,序贯
癌,小細胞肺/放化療法%老年%放化療法,同期%放化療法,序貫
암,소세포폐/방화요법%노년%방화요법,동기%방화요법,서관
small cell lung carcinoma%elderly%concurrent chemotherapy and radiotherapy%sequential chemotherapy and radiotherapy
目的 探讨同期放化疗在老年局限期小细胞肺癌治疗中的价值.方法 回顾分析2006-2011年本院行根治性胸部放疗的168例局限期小细胞肺癌患者临床资料,将年龄≥65岁者定义为老年组(53例),< 65岁者定义为非老年组(115例),对比不同治疗模式在老年和非老年患者的疗效及不良反应差异.结果 随访率为95.2%(两组分别失访4例).全组中位OS为24.6个月,中位PFS期为15.4个月.老年患者同期放化疗和序贯放化疗的中位OS分别为15.9个月和24.6个月(P =0.013),3、4级血液学不良反应发生率分别为13.3%和2.6% (P=0.170);非老年患者同期放化疗和序贯放化疗的中位OS分别为39.6个月和24.5个月(P=0.018),不良反应发生率相近(P=0.250 ~0.757).结论 老年局限期小细胞肺癌同期放化疗的实施要谨慎进行,序贯放化疗可能是一种替代选择.
目的 探討同期放化療在老年跼限期小細胞肺癌治療中的價值.方法 迴顧分析2006-2011年本院行根治性胸部放療的168例跼限期小細胞肺癌患者臨床資料,將年齡≥65歲者定義為老年組(53例),< 65歲者定義為非老年組(115例),對比不同治療模式在老年和非老年患者的療效及不良反應差異.結果 隨訪率為95.2%(兩組分彆失訪4例).全組中位OS為24.6箇月,中位PFS期為15.4箇月.老年患者同期放化療和序貫放化療的中位OS分彆為15.9箇月和24.6箇月(P =0.013),3、4級血液學不良反應髮生率分彆為13.3%和2.6% (P=0.170);非老年患者同期放化療和序貫放化療的中位OS分彆為39.6箇月和24.5箇月(P=0.018),不良反應髮生率相近(P=0.250 ~0.757).結論 老年跼限期小細胞肺癌同期放化療的實施要謹慎進行,序貫放化療可能是一種替代選擇.
목적 탐토동기방화료재노년국한기소세포폐암치료중적개치.방법 회고분석2006-2011년본원행근치성흉부방료적168례국한기소세포폐암환자림상자료,장년령≥65세자정의위노년조(53례),< 65세자정의위비노년조(115례),대비불동치료모식재노년화비노년환자적료효급불량반응차이.결과 수방솔위95.2%(량조분별실방4례).전조중위OS위24.6개월,중위PFS기위15.4개월.노년환자동기방화료화서관방화료적중위OS분별위15.9개월화24.6개월(P =0.013),3、4급혈액학불량반응발생솔분별위13.3%화2.6% (P=0.170);비노년환자동기방화료화서관방화료적중위OS분별위39.6개월화24.5개월(P=0.018),불량반응발생솔상근(P=0.250 ~0.757).결론 노년국한기소세포폐암동기방화료적실시요근신진행,서관방화료가능시일충체대선택.
Objective We aimed to investigate whether the standard approach of concurrent chemotherapy and radiation is an appropriate choice for elderly patients with limited-stage small-cell lung cancer (LS-SCLC).Methods A total of 168 LS-SCLC patients who had received thoracic radiotherapy from January 2006 to December 2011 at our institution were included in this retrospective study.Patients aged 65 years or older were defined as elder,and we compare concurrent chemoradiotherapy (CCRT) to sequential chemoradiotherapy (SCRT) in the elderly group (53 patients) and in its younger (153 patients) counterpart.Results The follow-up rate was 95.2% (each of the two groups lost in 4 patients).The median OS and PFS for the entire cohort was 24.6 months and 15.4 months.Among the elderly patients,the median OS were 15.9 and 24.6 months (P =0.013) in the CCRT and SCRT subgroups,respectively,and the toxicity were similar except for that more grade 3/4 hematological toxicity events were observed in the CCRT subgroup (13.3% versus 2.6%,P =0.170).Among the young patients,the median OS was 39.6 months in the CCRT subgroup and 24.5 months in the SCRT group (P =0.018),and no significant differences occurred in toxicity between the two subgroups (P=0.250-0.757).Conclusions Concurrent chemoradiotherapy should be used with caution in elderly patients,and sequential chemotherapy may be an alternative choice.